Related Experiment Video
Updated: May 20, 2026
06:47
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Relationship between dyslipidemia and gene polymorphism in Tibetan population
Ling Xia Zhang1, Ying Sun, Yu Liang
1Institute of Tuberculosis, The 309th Hospital of Chinese People's Liberation Army, Beijing 100091, China.
Biomedical and Environmental Sciences : BES
|July 31, 2012
Summary
Specific genetic variations (SNPs) are linked to triglyceride levels in the Tibetan population. These findings highlight potential gene associations, including APOA5 and MLXIPL, for serum triglyceride regulation in this ethnic group.
Area of Science:
- Genetics
- Biochemistry
- Population Health
Background:
- Dyslipidemia prevalence is a growing concern globally, particularly in diverse ethnic groups.
- Understanding genetic predispositions to dyslipidemia is crucial for targeted interventions.
- The Tibetan population presents unique genetic and environmental factors influencing metabolic health.
Purpose of the Study:
- To investigate the association between single nucleotide polymorphisms (SNPs) and blood lipid levels in the Tibetan population.
- To identify specific SNPs related to triglyceride (TG) levels in this ethnic group.
- To explore the potential role of APOA5 and MLXIPL genes in serum TG regulation.
Main Methods:
- Random cluster sampling across five Tibetan regions (Lhasa, Shigatse, Shannan, Nagqu, Nyingchi).
- Measurement of serum lipid profiles: total cholesterol (TC), triglyceride (TG), HDL-C, and LDL-C.
- DNA extraction and genotyping for SNP analysis, followed by statistical correlation.
Main Results:
- A dyslipidemia prevalence of 27.8% was observed in 1,318 Tibetan adults (>18 years).
- SNPs rs714052 and rs964184 showed a significant correlation with serum triglyceride levels.
- Specific genotypes (e.g., rs714052 CC, rs964184 CC) were associated with lower TG levels, while others (e.g., rs714052 TT, rs964184 GG) were linked to higher TG levels.
Conclusions:
- Several SNPs are significantly associated with serum triglyceride levels in the Tibetan population.
- The APOA5 and MLXIPL genes are potentially closely linked to serum TG levels in this ethnic group.
- These findings contribute to understanding the genetic basis of dyslipidemia in Tibetans.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...